> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # The FDA Just Told an Exosome Seller Its Product Probably Contains No Exosomes - URL: https://compounded.ghost.io/the-fda-just-told-an-exosome-seller-its-product-probably-contains-no-exosomes/ - Published: 2026-10-11T11:15:37.000Z - Updated: 2026-10-11T11:15:36.000Z - Author: Connor Hayes In August the FDA posted a warning letter to a network of companies selling injectable products derived from umbilical cord blood, Wharton's jelly and what the firms marketed as exosomes. The agency's findings covered the usual ground for this corner of the industry: unapproved new drugs, unlicensed biologics, aseptic processes that had never been validated, a two-year expiration date with no stability data behind it. Then it added something sharper. Based on the manufacturing process the inspectors observed, the agency said it did not appear the process would isolate exosomes at all. That single line is the most useful thing to come out of regenerative medicine enforcement this year, because it moves the question from whether these products work to whether they are what the label says. Those are different problems, and only one of them gets discussed in clinic marketing. ### From the Lab to the Ledger Exosomes are real biology. Cells package proteins, lipids and RNA into tiny membrane-bound vesicles and release them, and those vesicles carry signals to other cells. The scientific interest is genuine: if you could capture the signaling output of a useful cell type without transplanting the cell itself, you would have something easier to store, standardize and dose than a living graft. The gap is between that idea and what is being sold. Isolating exosomes is technically demanding. They are nanometer-scale particles that have to be separated from a soup of similar-sized debris, free proteins and cell fragments, which takes specific equipment and verification that what you collected is actually the vesicle population you wanted. A process that simply spins down and filters conditioned cell culture or birth tissue yields a mixture. Calling that mixture exosomes is a characterization claim, and characterization is exactly what the agency found missing. The regulatory frame matters too. In the United States, a cell or tissue product can be handled as a lightly regulated human tissue only if it is minimally manipulated and used for the same basic function it served in the donor. Processing birth tissue into an injectable intended to treat joint pain or neurological conditions falls outside that, which makes it a biologic drug requiring approval. There are currently no approved exosome therapies for any condition. ### Bio-Pipeline Ledger Approved exosome therapies: none exist in the United States for any indication. Every clinical exosome product on the market is being sold outside the approval pathway. Clinical-stage exosome research: legitimate trials are underway in areas including drug delivery and tissue repair, generally early phase with no validated efficacy endpoint yet. Early clinical stage, genuinely promising as a research direction. Approved cell therapies from birth tissue: cord blood units for hematopoietic transplantation are licensed and well validated for specific blood and immune disorders. Commercially available, and narrowly indicated. Autologous bone marrow and adipose injections for joints: widely offered in clinics, with trial results that remain mixed and largely unable to show benefit over placebo injection for osteoarthritis. Inconclusive after years of study. Clinic-sold stem cell and exosome injections for neurological, autoimmune or anti-aging use: no approval, no validated evidence base, and now documented sterility and identity problems in at least one large network. Not validated for broad use. ### The Clinical Reality Check The useful takeaway is not that regenerative medicine is empty. Cord blood transplantation is real medicine. Cell and gene therapies have won approvals in sickle cell disease, inherited retinal disease and several cancers, built on years of controlled trials. The field has delivered. What has not delivered is the clinic layer selling injections on the strength of the field's reputation rather than its own data. The warning letter is a reminder that when a product sits outside the approval system, three separate assurances disappear together: that it works, that it is sterile, and that it contains what it claims. Most patient conversations focus on the first. The agency's findings on unvalidated aseptic processing and compromised sterility testing concern the second, which is the one that can hurt someone this week rather than disappoint them next year. Practical questions are better than skepticism in the abstract. Is this product approved, and for what. Is it being administered inside a registered clinical trial with an IND, which can be checked independently. What testing confirms its identity and sterility, and who performed it. A provider who cannot answer those plainly has answered them. The enforcement signal is worth tracking, because this letter came from facility inspections rather than a website review, and the agency noted the same principal had been warned about similar claims seven years earlier. That pattern is how civil matters become criminal ones. For anyone treating health as infrastructure worth protecting, the lesson is unglamorous: the paperwork around a therapy is not bureaucracy to be routed around. It is the only thing standing between a promising mechanism and an unlabeled vial. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/10/exosome-clinics-fda-enforcement-3-editorial.jpg) ###